摘要
目的:系统评价喜炎平注射液联合利巴韦林治疗小儿轮状病毒肠炎的临床疗效和安全性。方法:计算机检索CNKI、VIP、WanFang Data、SinoMed、PubMed、The Cochrane Library和EMbase数据库,搜集有关喜炎平注射液联合利巴韦林治疗小儿轮状病毒肠炎的随机对照试验(RCT),检索时限均为从建库至2021年12月24日。由两名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.4软件进行Meta分析。结果:共纳入11个RCT,共计1164例患儿。Meta分析结果显示,在常规治疗的基础上,与仅用利巴韦林(对照组)相比,喜炎平注射液联用利巴韦林(试验组)能够提高总有效率[RR=1.24,95%CI(1.18,1.30),P<0.001]。此外,喜炎平注射液联用利巴韦林还可适当缩减患儿腹泻、恶心呕吐、腹痛、腹鸣时间。安全性方面,3项研究明确表明没有明显药品不良反应,3项研究共报告15例药品不良反应,其中试验组6例,对照组9例。结论:当前证据表明,与仅用利巴韦林相比,喜炎平注射液联合利巴韦林治疗小儿轮状病毒肠炎能提高总有效率,缩减患儿腹泻、恶心呕吐、腹痛、腹鸣时间,安全性有待进一步研究。
Objective:To systematically review the effectiveness and safety of Xiyanping injection combined with ribavirin in the treatment of infantile rotavirus enteritis in children.Methods:Databases including CNKI,VIP,WanFang Data,SinoMed,PubMed,The Cochrane Library and EMbase were searched to collect randomized controlled trials(RCTs)about Xiyanping injection combined ribavirin in the treatment of infantile rotavirus enteritis in children from the inception to December 24th,2021.Two reviewers independently screened literature,extracted data,and assessed the risk of bias of in⁃cluded studies,then,meta⁃analysis was performed by using RevMan 5.4 software.Results:A total of 11 RCTs including 1164 patients were included.The results of meta⁃analysis showed that on the basis of routine therapy,compared with riba⁃virin(control group),Xiyanping injection with ribavirin(experimental group)could improve total effective rate(RR=1.24,95%CI 1.18 to 1.30,P<0.001),shorten the time of diarrhea,vomiting,abdominal pain and abdominal ringing.There were no obvious adverse reactions in the three studies,and 15 cases of adverse reactions were reported in the three studies,including 6 cases in the experimental group and 9 cases in the control group.Conclusion:The current evidence shows that,compared with ribavirin,Xiyanping injection combined with ribavirin can improve total effective rate,shorten the time of diarrhea,vomiting,abdominal pain and abdominal ringing.The safety of Xiyanping injection needs further study.
作者
巴合班·叶尔江
巫志姗
王伟
王郝嘉
伍超
陆珊
黄志鸿
谭影影
吴嘉瑞
Baheban·Yeerjiang;Wu Zhishan;Wang Wei;Wang Haojia;Wu Chao;Lu Shan;Huang Zhihong;Tan Yingying;Wu Jiarui(School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing 100102,China;Lu’nan Pharmaceutical Group Co.,Ltd.,State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine)
出处
《药物流行病学杂志》
CAS
2022年第12期787-793,共7页
Chinese Journal of Pharmacoepidemiology
基金
国家自然科学基金项目(编号:82074284)
国家中医药传承与创新团队子项目(编号:ZYYCXTD⁃202005⁃10)。
